Mechanisms in failure of infliximab for Crohn's disease (Q73197599)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Mechanisms in failure of infliximab for Crohn's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

S Nikolaus

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Raedler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

T Kühbacker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Sfikas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

U R Fölsch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Schreiber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

356

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

9240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1475-1479

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

Disease activity courses in a regional cohort of Crohn's disease patients

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Frequency of glucocorticoid resistance and dependency in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

NF-kappa B subunit-specific regulation of the interleukin-8 promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

The NF-kappa B and I kappa B proteins: new discoveries and insights

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

An interleukin-4-induced transcription factor: IL-4 Stat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Activation of nuclear factor kappa B inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902871-3

7 January 2021

10.1016/S0140-6736(00)02871-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11081530%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference